Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameKindstar Global
Stock Code09960
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是中國領先的獨立臨床特檢服務提供商,擁有最大的特檢組合,提供逾3,500種檢驗項目,涵蓋血液學、遺傳病及罕見病、傳染病、腫瘤、神經學及婦科相關疾病等專科領域,為醫院及患者提供臨床檢驗服務,並為合約研究機構、製藥公司及研究機構提供檢測服務。
Listing Date2021-07-16
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國湖北省武漢市東湖新技術開發區高新大道666號光谷生物城生物創新園D2-1
Business Address (Hong Kong)香港皇后大道東183號合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.kindstar.com.cn
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 9.78 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 4,890
Par ValueTo be extracted
Offer Period2021-06-29 to 2021-07-07
Global Offering Shares226,405,000 shares
HK Public Offer Shares (Initial)22,640,500 shares (10.0%)
Public Offer Lots (Initial)45,281lots (Pool A22,640lots,Pool B22,641lots)
International Placing Shares (Initial)203,764,500 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO905,619,120 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share49.1%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 2,214,240,900

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 4,890
2 lots 1,000 HK$ 9,780
3 lots 1,500 HK$ 14,670
4 lots 2,000 HK$ 19,560
5 lots 2,500 HK$ 24,450
6 lots 3,000 HK$ 29,340
7 lots 3,500 HK$ 34,230
8 lots 4,000 HK$ 39,120
9 lots 4,500 HK$ 44,010
10 lots 5,000 HK$ 48,900
12 lots 6,000 HK$ 58,680
14 lots 7,000 HK$ 68,460
16 lots 8,000 HK$ 78,240
18 lots 9,000 HK$ 88,020
20 lots 10,000 HK$ 97,800
30 lots 15,000 HK$ 146,700
40 lots 20,000 HK$ 195,600
50 lots 25,000 HK$ 244,500
60 lots 30,000 HK$ 293,400
70 lots 35,000 HK$ 342,300
80 lots 40,000 HK$ 391,200
90 lots 45,000 HK$ 440,100
100 lots 50,000 HK$ 489,000
120 lots 60,000 HK$ 586,800
140 lots 70,000 HK$ 684,600
160 lots 80,000 HK$ 782,400
180 lots 90,000 HK$ 880,200
200 lots 100,000 HK$ 978,000
400 lots 200,000 HK$ 1,956,000
600 lots 300,000 HK$ 2,934,000
800 lots 400,000 HK$ 3,912,000
1,000 lots 500,000 HK$ 4,890,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1,200 lots 600,000 HK$ 5,868,000
1,400 lots 700,000 HK$ 6,846,000
1,600 lots 800,000 HK$ 7,824,000
1,800 lots 900,000 HK$ 8,802,000
2,000 lots 1,000,000 HK$ 9,780,000
4,000 lots 2,000,000 HK$ 19,560,000
6,000 lots 3,000,000 HK$ 29,340,000
8,000 lots 4,000,000 HK$ 39,120,000
10,000 lots 5,000,000 HK$ 48,900,000
12,000 lots 6,000,000 HK$ 58,680,000
14,000 lots 7,000,000 HK$ 68,460,000
16,000 lots 8,000,000 HK$ 78,240,000
18,000 lots 9,000,000 HK$ 88,020,000
20,000 lots 10,000,000 HK$ 97,800,000
22,640 lots 11,320,000 HK$ 110,709,600

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 1.06B
Est. Threshold HK$ 9.69B
Analysis Result HK market cap below threshold, need +818%

Valuation & Financials

Market Cap (at Offer Price)HK$ 8,856,954,993
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損人民幣970.1百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201820192020
Revenue 706,202832,791891,391
Cost of sales -327,806-380,577-430,410
Gross profit 378,396452,214460,981
Other income and gains, net 13,82916,87039,598
Selling and distribution expenses -249,528-274,599-248,521
Administrative expenses -41,890-48,734-52,320
Net finance costs -4,189-3,536-2,327
Profit before tax -59,415-168,605-962,352
Income tax expense 5,066-977-7,768
Profit for the year -54,349-169,582-970,120
Profit attributable to owners -52,674-169,788-974,020
Balance Sheet
Item 201820192020
Cash and cash equivalents 26,62059,510841,227
Trade and bills receivables 201,303237,790310,385
Inventories 31,04141,17344,977
Total current assets 313,678446,1271,355,235
Total assets 576,537664,4231,576,959
Total current liabilities 1,153,8611,434,900530,661
Total liabilities 1,194,4611,463,8443,411,374
Total equity -617,924-799,421-1,834,415
Equity attributable to owners -622,102-804,125-1,843,802
Interest-bearing borrowings 0040,000
Cash Flow Statement
Item 201820192020
Net cash from operating activities 53,89599,44873,462
Net cash from investing activities -73,708-47,547-121,960
Net cash from financing activities -3,081-18,902851,925
Net increase in cash -22,89432,999803,427
Depreciation of PP&E 22,50526,14734,471
Depreciation of right-of-use assets 14,48415,43215,243
Amortisation of intangible assets 7831,0231,081
Purchase of PP&E -58,260-38,351-23,200
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 9.04
First Day OpenHK$ 9.78
First Day Change-7.57%
First Day Volume97344700.0
First Day Turnover905213000.0
Use of Proceeds
1、約35%或718.8百萬港元將分配至銷售及營銷我們現有的特檢服務線以涵蓋更多醫院,尤其是三級醫院; 2、約20%或410.7百萬港元將分配至現有特檢服務線的研發,以采用創新檢測技術及持續擴大我們的檢測服務組合; 3、約15%或308.0百萬港元將分配至新特檢服務線的開發及商業化以進一步擴大我們的服務范圍; 4、約5%或102.7百萬港元將分配至撥資收購與我們的現有業務產生互補及協同效應的具吸引力的技術或檢測相關公司; 5、約10%或205.4百萬港元將分配至加強我們的檢測能力,包括擴充及升級我們的檢測設施、檢測設備及儀器以及招聘額外檢測及診斷技術人員; 6、約5%或102.7百萬港元將分配至向海外擴張至中國以外的市場,旨在滿足東南亞及中東發展中國家的未滿足醫療需求; 7、約10%或205.4百萬港元預期將用作營運資金及其他一般公司用途。

Underwriting Syndicate

Joint Sponsors (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 Credit Suisse (Hong Kong) Limited CE AAO017
Overall Coordinators (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 Credit Suisse (Hong Kong) Limited CE AAO017
Joint Bookrunners (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 Credit Suisse (Hong Kong) Limited CE AAO017
Joint Lead Managers (6)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 Credit Suisse (Hong Kong) Limited CE AAO017 VMS Securities Limited CE AAC621 国泰君安证券(香港)有限公司 CE ABY236 富途证券国际(香港)有限公司 CE AZT137

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Athos Asia Event Driven Master Fund 77,623,860 HKD — 3.51% — 6 months 2022-01-16
2 BlackRock Funds 310,510,110 HKD — 14.02% — 6 months 2022-01-16
3 Carmignac Funds 116,440,680 HKD — 5.26% — 6 months 2022-01-16
4 CPE Funds 271,693,290 HKD — 12.27% — 6 months 2022-01-16
5 DNCA Finance 116,440,680 HKD — 5.26% — 6 months 2022-01-16
6 Snow Lake China Master Fund, Ltd. 155,252,610 HKD — 7.01% — 6 months 2022-01-16
7 常春藤资产管理(香港)有限公司 38,811,930 HKD — 1.75% — 6 months 2022-01-16

Directors & Management

PositionChinese nameEnglish Name
Chairman黃士昂—
Company Secretary柴海節、陳蕙玲—
No director data available.

Major Shareholders

Major Shareholders & Holdings黃醫生持股16.05%,Huang Bo先生持股10.96%,黃瑞瑨先生持股10.37%,HCA Investments持股10.06%,寧波瑞伏持股8.01%,CK Lab Tech持股8.87%等(假設超額配股權未獲行使)。
About this page

This page shows Kindstar Global (09960) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect